Results 31 to 40 of about 926 (182)

Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis. [PDF]

Aliment Pharmacol Ther
Peroxisome proliferator‐activated receptor (PPAR) agonists have emerged as important second‐line treatments in primary biliary cholangitis, with profiles influenced by different selectivity for α‐, δ‐ and γ‐isoforms. PPAR‐α and PPAR‐δ agonism improve cholestasis, with inflammation reduced via all isoforms. PPAR‐δ agonism also reduces pruritus.
Schattenberg JM, Banales JM, Hirschfield G, Trivedi P, Cable EE, McWherter CA, Billin AN, Crittenden DB, Budas G.   +8 more
europepmc   +2 more sources

Saroglitazar ameliorates monosodium glutamate-induced obesity and associated inflammation in Wistar rats: Plausible role of NLRP3 inflammasome and NF- κB [PDF]

Iranian Journal of Basic Medical Sciences, 2022
Objective(s): Inflammation is the major progenitor of obesity and associated metabolic disorders. The current study investigated the modulatory role of saroglitazar on adipocyte dysfunction and associated inflammation in monosodium glutamate (MSG) obese ...
Sayima Nabi, Uma Bhandari, Syed Haque
doaj   +1 more source

Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]

Drug Design, Development and Therapy, 2021
Syed Hasan Shuja, Farea Eqbal, Hafsa Rehman Dow Medical College, Karachi, Sindh, PakistanCorrespondence: Syed Hasan ShujaDow Medical College, Dow University of Health Sciences, Baba-e-Urdu Road, Karachi, 74200, PakistanTel +923200250770Email hasanshuja6@gmail.com View the original paper by Dr Fraile and ...
Syed Hasan Shuja, Farea Eqbal, Hafsa Rehman   +2 more
openaire   +4 more sources

Role of Saroglitazar in Non Diabetic Non Alcoholic Fatty Liver Disease Patients: A Retrospective Observational Study [PDF]

Journal of Clinical and Diagnostic Research, 2021
Introduction: Non Alcoholic Fatty Liver Disease (NAFLD) is a commonly encountered problem which affects one third of the general population. Saroglitazar, a Peroxisome Proliferator Activated Receptor (PPAR) alpha α and gamma γ agonist has been ...
Akash Jaiswal, Kavita Jain, Amit Kumar Singh   +2 more
doaj   +1 more source

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

BMC Pharmacology and Toxicology, 2021
Background Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have become significant global health concerns. In the present study, we aimed to investigate the effects of saroglitazar, a dual PPARα/γ agonist, fenofibrate ...
Rasoul Akbari, Tahereh Behdarvand, Reza Afarin, Hamid Yaghooti, Mohammad Taha Jalali, Narges Mohammadtaghvaei   +5 more
doaj   +1 more source

Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL/6J mice

Heliyon, 2023
We evaluated the effects of select herbal extracts (Tinospora cordifolia [TC], Tinospora cordifolia with Piper longum [TC + PL], Withania somnifera [WS], Glycyrrhiza glabra [GG], AYUSH–64 [AY-64], and Saroglitazar [S]) on various parameters in a diet ...
Deepika Kumari, Jyoti Gautam, Vipin Sharma, Sonu Kumar Gupta, Soumalya Sarkar, Pradipta Jana, Vikas Singhal, Prabhakar Babele, Parul Kamboj, Sneh Bajpai, Ruchi Tandon, Yashwant Kumar, Madhu Dikshit   +12 more
doaj   +1 more source

Saroglitazar: A New Drug to Treat Diabetic Hypertriglyceridemia

Heart Research - Open Journal, 2017
Vineet Bhatia, Parneesh Arora, Gagandeep Kaur, Upendera Kaul   +3 more
openaire   +2 more sources

Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients.

, 2023
NAFLD is common after liver transplantation (LT) and is associated with an increased metabolic burden. Currently, there is a paucity of investigations into the treatment of post-LT NAFLD.
Siddiqui, Mohammad Shadab, Parmar, Deven, Bui, Anh Tuan, Patel, Vaishali, Patel, Samarth S, MD, Shaikh, Farheen, Boyett, Sherry, Forsgren, Mikael, Sanyal, Arun J   +8 more
core   +2 more sources

Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2mg on total cholesterol (mg/dL).

, 2022
Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2mg on total cholesterol (mg/dL).
Manik Chhabra (10822587), Kota Vidyasagar (10822584), Muhammed Rashid (10822590), Rishabh Sharma (6505124), Sai Krishna Gudi (12559618), Jatin Sharma (7408166)   +5 more
core   +1 more source

Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2mg on LDL-cholesterol (mg/dL).

, 2022
Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2mg on LDL-cholesterol (mg/dL).
Manik Chhabra (10822587), Kota Vidyasagar (10822584), Muhammed Rashid (10822590), Rishabh Sharma (6505124), Sai Krishna Gudi (12559618), Jatin Sharma (7408166)   +5 more
core   +1 more source